Securities Report – 24th Fiscal Period (2025/04/01 – 2026/03/31)

ReproCELL Inc. Securities Report – 24th Fiscal Period (2025/04/01 – 2026/03/31)

This document is the securities report submitted by ReproCELL Inc. (hereinafter referred to as "the Company") in accordance with the Financial Instruments and Exchange Act, covering the Company's business results, financial condition, and cash flow status for the 24th fiscal period (from April 1, 2025 to March 31, 2026).

The Company operates as a biotechnology enterprise focused on drug discovery for regenerative medicine and neurodegenerative diseases, conducting research and development utilizing iPS cell technology both domestically and internationally. This report provides detailed disclosures on consolidated and individual financial statements, management policies, business overview, R&D progress, executive compensation, shareholder composition, risk factors, and future outlook.

Notably, preclinical development of therapeutic candidates targeting Alzheimer's and Parkinson's diseases is ongoing, with plans to advance certain candidates into clinical trials during the 2025 fiscal year. Additionally, sales of the drug discovery support service "NeuroScreen" continue to grow steadily, contributing to diversified revenue streams.

The Company will continue transparent disclosure practices and remain committed to building trust with investors and other stakeholders.